CELL AND GENE THERAPY CATAPULT
Untargeted metabolomics of cell-free media from suspension-adapted cells producing adeno-associated viruses
The procurement contact named on the official notice.
The submission route named on the official notice.
This is a large award for Research & Development — above three-quarters of comparable contracts. Based on 20,405 valued Research & Development tenders in our corpus.
CELL AND GENE THERAPY CATAPULT publishes Research & Development work continuously — 5 notices, roughly one every 49 days. This is a stream to watch, not a cycle to wait for.
44% of CELL AND GENE THERAPY CATAPULT’s awards go to a supplier it has used before.
Which is the argument for getting on the list rather than winning this one. The incumbent is rarely the last winner — it is the roster. See the retention odds by category →
Cell Therapy Catapult Ltd is seeking through this Open Tender Process to contract with a suitably capable Bidder to provide the Services for the untargeted metabolomics of cell-free media from suspension-adapted cells producing adeno-associated viral vectors (AAV).
Briefly, human cells will be subjected to AAV production in parallel with controls.
A maximum of 35 sample and two medium controls will be generated in this experiment, designated as "Run 1", and sent to the awarded Bidder each as technical replicates (maximum 3 per sample).
The samples will then be processed by the awarded Bidder as per requirements detailed in Specification (Appendix B).
In addition to "Run 1", two additional runs ("Run 2" and "Run 3") may be performed at our sole discretion.
Importantly, the experimental setup for both "Run 2" and "Run 3" will be similar to that for "Run 1", but sample numbers may differ if additional conditions are included or excluded.
A maximum of 37 samples (i.e., including medium controls) will be obtained for either "Run 2" and "Run 3".
Subsequent runs or analysis may be performed, contingent on the results obtained from the 3 planned runs.
This will be to ensure robustness of the findings or to meet unforeseen project needs.
This will be based on satisfactory performance and continued need.
What the notice asks for
This will be to ensure robustness
This will be to ensure robustness of the findings or to meet unforeseen project needs.
Sentences from the notice that state an obligation, surfaced automatically and shown in the order they appear. Not an exhaustive list — always confirm against the tender documents.
Make the case to bid
Reveal who to approach at CELL AND GENE THERAPY CATAPULT, and generate a go-to-market strategy from their news, accounts and people.
Free to start. Named contacts come from published notices; the strategy is generated from the buyer’s news, accounts and people.
The full intelligence dossier
Our agent reads CELL AND GENE THERAPY CATAPULT’s accounts, hunts live signals, finds the people who decide — and hands you a bid strategy plus a go-to-market influence plan, including what your team should post this week. You approve every paid step.
Five included while we’re in beta, and the agent asks before it spends on any paid step.
- OCID
- ocds-h6vhtk-037448
- Stage
- tender · Open
- Source
- Find a Tender
- Buyer ref
- 028371-2022
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
Top suppliers & buyers in Research & Development
CELL AND GENE THERAPY CATAPULT’s tender network